TrialFuture oncology (London, England)2024

Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.

Changhoon Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.